[go: up one dir, main page]

MA31352B1 - Dérivés imidazolidine carboxamide comme modulateurs de p2x7. - Google Patents

Dérivés imidazolidine carboxamide comme modulateurs de p2x7.

Info

Publication number
MA31352B1
MA31352B1 MA32245A MA32245A MA31352B1 MA 31352 B1 MA31352 B1 MA 31352B1 MA 32245 A MA32245 A MA 32245A MA 32245 A MA32245 A MA 32245A MA 31352 B1 MA31352 B1 MA 31352B1
Authority
MA
Morocco
Prior art keywords
pain
receptor
imidazolidin
carboxamide derivatives
compounds
Prior art date
Application number
MA32245A
Other languages
Arabic (ar)
English (en)
Inventor
Paul John Beswick
David Kenneth Dean
Robert James Gleave
Andrew Peter Moses
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706501A external-priority patent/GB0706501D0/en
Priority claimed from GB0720653A external-priority patent/GB0720653D0/en
Priority claimed from GB0805272A external-priority patent/GB0805272D0/en
Priority claimed from GB0805504A external-priority patent/GB0805504D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31352B1 publication Critical patent/MA31352B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci. Les composés ou les sels modulent la fonction récepteur de p2x7 et peuvent antagoniser les effets de atp au niveau du récepteur de p2x7 (antagonistes du récepteur de p2x7). L'invention concerne également l'utilisation de ces composés ou sels, ou des compositions pharmaceutiques de ceux-ci dans le traitement ou la prévention de troubles/maladies médiés par le récepteur de p2x7, par exemple la douleur, l'inflammation ou une maladie neurodégénérative, en particulier la douleur telle que la douleur inflammatoire, la douleur neuropathique ou la douleur viscérale.
MA32245A 2007-04-03 2009-10-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7. MA31352B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0706501A GB0706501D0 (en) 2007-04-03 2007-04-03 Novel compounds
GB0720653A GB0720653D0 (en) 2007-10-22 2007-10-22 Novel compounds
GB0805272A GB0805272D0 (en) 2008-03-20 2008-03-20 Novel compounds
GB0805504A GB0805504D0 (en) 2008-03-26 2008-03-26 Compounds
PCT/EP2008/053962 WO2008119825A2 (fr) 2007-04-03 2008-04-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7

Publications (1)

Publication Number Publication Date
MA31352B1 true MA31352B1 (fr) 2010-05-03

Family

ID=39673302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32245A MA31352B1 (fr) 2007-04-03 2009-10-02 Dérivés imidazolidine carboxamide comme modulateurs de p2x7.

Country Status (15)

Country Link
US (1) US7932282B2 (fr)
EP (1) EP2142512A2 (fr)
JP (1) JP2010523524A (fr)
KR (1) KR20090127435A (fr)
CN (1) CN101679291A (fr)
AU (1) AU2008234855B2 (fr)
BR (1) BRPI0809930A2 (fr)
CA (1) CA2682649A1 (fr)
CR (1) CR11089A (fr)
DO (1) DOP2009000231A (fr)
EA (1) EA200970912A1 (fr)
IL (1) IL201202A0 (fr)
MA (1) MA31352B1 (fr)
MX (1) MX2009010759A (fr)
WO (1) WO2008119825A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714062A2 (pt) * 2006-07-06 2012-12-18 Glaxo Group Ltd n-fenil-metil-5-oxo-prolina-2-amidas substituìdas como antagonistas do receptor da p2x, e os seus métodos de uso
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
EP2459541A1 (fr) * 2009-07-30 2012-06-06 F. Hoffmann-La Roche AG Amides de dihydropyrimidone utilisés comme modulateurs p2x7
DK2848256T3 (en) 2009-12-08 2019-03-04 Univ Vanderbilt Improved vein harvesting and autotransplantation methods and compositions
WO2011109833A2 (fr) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Compositions de cellules dendritiques induites et utilisations associées
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
ES2786298T3 (es) * 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR102033190B1 (ko) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
EP2935211B1 (fr) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7
CN104918946B (zh) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CA2896790C (fr) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
CA3025718A1 (fr) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Derives de pyrazole en tant qu'inhibiteurs de la kallicreine plasmatique
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
WO2021257490A1 (fr) * 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxoimidazolidine-4-carboxamides utilisés en tant qu'inhibiteurs de nav1.8
CN115650920B (zh) * 2022-11-16 2023-03-31 山东金城柯瑞化学有限公司 制备药物中间体(4s)-1-甲基-2-氧代咪唑啉-4-羧酸叔丁酯的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5024287A (fr) 1973-06-28 1975-03-15
JP2830528B2 (ja) 1991-07-25 1998-12-02 東洋インキ製造株式会社 シート状物保持装置
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB0324498D0 (en) * 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
BRPI0714062A2 (pt) * 2006-07-06 2012-12-18 Glaxo Group Ltd n-fenil-metil-5-oxo-prolina-2-amidas substituìdas como antagonistas do receptor da p2x, e os seus métodos de uso

Also Published As

Publication number Publication date
MX2009010759A (es) 2009-10-28
DOP2009000231A (es) 2009-11-15
WO2008119825A2 (fr) 2008-10-09
CN101679291A (zh) 2010-03-24
CA2682649A1 (fr) 2008-10-09
JP2010523524A (ja) 2010-07-15
WO2008119825A3 (fr) 2008-12-11
AU2008234855B2 (en) 2011-01-20
US7932282B2 (en) 2011-04-26
AU2008234855A1 (en) 2008-10-09
BRPI0809930A2 (pt) 2014-10-07
EA200970912A1 (ru) 2010-02-26
EP2142512A2 (fr) 2010-01-13
IL201202A0 (en) 2010-05-17
KR20090127435A (ko) 2009-12-11
CR11089A (es) 2010-03-08
US20100075968A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
MA31352B1 (fr) Dérivés imidazolidine carboxamide comme modulateurs de p2x7.
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
DE602008005582D1 (de) Pyrazolderivate als p2x7-modulatoren
Fracon et al. Prostaglandins and bone: potential risks and benefits related to the use of nonsteroidal anti-inflammatory drugs in clinical dentistry
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
WO2009106980A3 (fr) Dérivés d'indazole
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EP2178870A4 (fr) Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA35576B1 (fr) Nouveaux composés
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30412B1 (fr) Composés Pharmaceutiques
MA33552B1 (fr) Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques
WO2008125600A3 (fr) Dérivés de pyrazole utilisés comme modulateurs de p2x7
WO2008119685A3 (fr) Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar